Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity.

Authors:
Otavio Cabral-Marques, Gilad Halpert, Lena F Schimke, Yuri Ostrinski, Aristo Vojdani, Gabriela Crispim Baiocchi, Paula Paccielli Freire, Igor Salerno Filgueiras, Israel Zyskind, Miriam T Lattin, Florian Tran, Stefan Schreiber, Alexandre H C Marques, Desirée Rodrigues Plaça, Dennyson Leandro M Fonseca, Jens Y Humrich, Antje Müller, Lasse M Giil, Hanna Graßhoff, Anja Schumann, Alexander Hackel, Juliane Junker, Carlotta Meyer, Hans D Ochs, Yael Bublil Lavi, Carmen Scheibenbogen, Ralf Dechend, Igor Jurisica, Kai Schulze-Forster, Jonathan I Silverberg, Howard Amital, Jason Zimmerman, Harry Heidecke, Avi Z Rosenberg, Gabriela Riemekasten, Yehuda Shoenfeld
Year of publication:
2022
Volume:
13
Issue:
1
Issn:
2041-1723
Journal title abbreviated:
NAT COMMUN
Journal title long:
Nature communications
Impact factor:
17.694
Abstract:
COVID-19 shares the feature of autoantibody production with systemic autoimmune diseases. In order to understand the role of these immune globulins in the pathogenesis of the disease, it is important to explore the autoantibody spectra. Here we show, by a cross-sectional study of 246 individuals, that autoantibodies targeting G protein-coupled receptors (GPCR) and RAS-related molecules associate with the clinical severity of COVID-19. Patients with moderate and severe disease are characterized by higher autoantibody levels than healthy controls and those with mild COVID-19 disease. Among the anti-GPCR autoantibodies, machine learning classification identifies the chemokine receptor CXCR3 and the RAS-related molecule AGTR1 as targets for antibodies with the strongest association to disease severity. Besides antibody levels, autoantibody network signatures are also changing in patients with intermediate or high disease severity. Although our current and previous studies identify anti-GPCR antibodies as natural components of human biology, their production is deregulated in COVID-19 and their level and pattern alterations might predict COVID-19 disease severity.